BIIBBiogen
$250.76+76% 1Y
$250.76
$143.0052 weeks$253.90
The financials
Biogen by the numbers
Biogen (BIIB) reported revenue of $2.74B in Q2 2026 (quarter ended Jun 30, 2026), up 3.4% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $98M (3.6% of revenue). For the full year FY2025, revenue was $9.89B (+2.2% year on year) and net income $1.29B. Its largest product in Q2 2026 was Royalty Attributed To OCREVUS at $381M, 13% of the disclosed total, just ahead of Rare Disease Product at 10.0%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $2.74B | $2.65B | +3.4% |
| Gross profit | $1.96B | $2.04B | −4.0% |
| Operating income | $132M | $744M | −82% |
| Net income | $98M | $635M | −85% |
| Diluted EPS | $0.66 | $4.33 | −85% |
| Product | Revenue | Share |
|---|---|---|
| Royalty Attributed To OCREVUS | $381M | 13% |
| Rare Disease Product | $295M | 10.0% |
| Tysabri Product | $271M | 9.2% |
| Product And Service Other | $242M | 8.2% |
| Contract Manufacturing And Other | $232M | 7.9% |
| Fumarate | $204M | 6.9% |
| SPINRAZA | $204M | 6.9% |
| VUMERITY | $172M | 5.8% |
| Interferon | $146M | 4.9% |
| Specialized Immunology | $128M | 4.3% |
| AVONEX | $121M | 4.1% |
| SYFOVRE | $97M | 3.3% |
| SKYCLARYS | $82M | 2.8% |
| Other Products | $71M | 2.4% |
| ZURZUVAE | $71M | 2.4% |
| Alzheimers Collaboration | $64M | 2.2% |
| LEQEMBI Collaboration | $64M | 2.2% |
| TECFIDERA | $32M | 1.1% |
| EMPAVELI | $30M | 1.0% |
| PLEGRIDY | $25M | 0.9% |
| Royalty | $10M | 0.3% |
| QALSODY | $8.3M | 0.3% |
| BYOOVIZ | $100K | 0.0% |
| Biosimilars | $100K | 0.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $2.95B (+25%)
Other Products grew +52% year on yearBiosimilars -96% year on year
Segment Latestquarter on quarteryear on year
- Royalty Attributed To OCREVUS$381.4M$381.4Mquarter on quarter +20%year on year +7.8%+20%+7.8%
- Rare Disease Product$294.9M$294.9Mquarter on quarter +31%year on year +26%+31%+26%
- Tysabri Product$270.5M$270.5Mquarter on quarter +12%year on year -0.62%+12%-0.62%
- Product And Service Other$242.4M$242.4Mquarter on quarter -1.8%year on year -0.90%-1.8%-0.90%
- Contract Manufacturing And Other$232.4M$232.4Mquarter on quarter -2.0%year on year +3.3%-2.0%+3.3%
- Fumarate$204.4M$204.4Mquarter on quarter +11%year on year -13%+11%-13%
- SPINRAZA$204.3M$204.3Mquarter on quarter +44%year on year +37%+44%+37%
- VUMERITY$172.0M$172.0Mquarter on quarter +12%year on year -8.5%+12%-8.5%
- Interferon$146.1M$146.1Mquarter on quarter +10%year on year -2.6%+10%-2.6%
- Specialized Immunology$127.8M$127.8Mquarter on quarter n/ayear on year n/an/an/a
- AVONEX$120.9M$120.9Mquarter on quarter +11%year on year -0.66%+11%-0.66%
- SYFOVRE$97.4M$97.4Mquarter on quarter n/ayear on year n/an/an/a
- SKYCLARYS$82.3M$82.3Mquarter on quarter +15%year on year +5.5%+15%+5.5%
- Other Products$70.7M$70.7Mquarter on quarter +28%year on year +52%+28%+52%
- ZURZUVAE$70.7M$70.7Mquarter on quarter +28%year on year +52%+28%+52%
- Alzheimers Collaboration$63.7M$63.7Mquarter on quarter +7.1%year on year +16%+7.1%+16%
- LEQEMBI Collaboration$63.7M$63.7Mquarter on quarter +7.1%year on year +16%+7.1%+16%
- TECFIDERA$32.4M$32.4Mquarter on quarter +3.2%year on year -31%+3.2%-31%
- EMPAVELI$30.4M$30.4Mquarter on quarter n/ayear on year n/an/an/a
- PLEGRIDY$25.2M$25.2Mquarter on quarter +3.7%year on year -11%+3.7%-11%
- Royalty$10.0M$10.0Mquarter on quarter +3.1%year on year -49%+3.1%-49%
- QALSODY$8.3M$8.3Mquarter on quarter -21%year on year +11%-21%+11%
- BYOOVIZ$100.0K$100.0Kquarter on quarter n/ayear on year -96%n/a-96%
- Biosimilars$100.0K$100.0Kquarter on quarter n/ayear on year -96%n/a-96%
- BENEPALI$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- FLIXABI$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- FUMADERM And ADUHELM$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- IMRALDI$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
Drug Manufacturers, General
The closest names by size in the same industry